Its PT-141, a patented therapeutic drug candidate, nasally administered peptide that is in clinical development for the treatment of both male and female sexual dysfunction.
The company has various preclinical drug candidates under investigation based on the MC family of receptors for various therapeutic indications, including sexual dysfunction, obesity, cachexia, and inflammation.
Further, it conducts additional clinical trials with its NeutroSpec, a proprietary radiolabeled monoclonal antibody product, used for imaging of patients with equivocal signs and symptoms of appendicitis.
Palatin was incorporated in 1986 and based in Cranbury, New Jersey.
